- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03458481
Phase 2 Study of Yimitasvir Phosphate Capsules
A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
A phase 2, multicenter, randomized, parallel Assigned, open-label study to explore the safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic genotype 1 HCV infection.
Approximately 120 HCV genotype 1 subjects without cirrhosis will be enrolled, treatment-experienced subjects are ≤20%, all subjects will be randomized (1:1) to one of the following two treatment groups by IWRS (Medidata Balance): a) DAG181 100 mg/ SOF 400 mg once daily for 12 weeks, b) DAG181 200 mg/ SOF 400 mg once daily for 12 weeks. Randomization will be stratified by "treatment-naive" or "treatment-experienced".
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Beijing
-
Beijing, Beijing, Cina, 100034
- Peking University first hospital
-
Beijing, Beijing, Cina, 100069
- Beijing Youan Hospital,Capital Medical University
-
Beijing, Beijing, Cina, 100044
- Peking University People's Hospital
-
-
Gansu
-
Lanzhou, Gansu, Cina, 730000
- The First Hospital of Lanzhou University
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou, Guangdong, Cina, 510060
- Guangzhou Eighth People's Hospital
-
-
Hainan
-
Haikou, Hainan, Cina, 570311
- Hainan General Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, Cina, 050051
- The Third Hospital of Hebei Medical University
-
-
Hubei
-
Wuhan, Hubei, Cina, 430060
- Renmin Hospital of Wuhan University
-
Wuhan, Hubei, Cina, 430022
- Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
-
Wuhan, Hubei, Cina, 430030
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology
-
-
Hunan
-
Changsha, Hunan, Cina, 410008
- Xiangyan Hospital, Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210003
- The Second Hospital of Nanjing
-
-
Jiangxi
-
Nanchang, Jiangxi, Cina, 330006
- The First Affiliated Hospital Of Nanchang University
-
-
Jilin
-
Chang Chun, Jilin, Cina, 130021
- The First Hospital of Jilin University
-
-
Shanxi
-
Xi'an, Shanxi, Cina, 710038
- Tangdu Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- West China Hospital, Sichuan University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Willing and able to provide written informed consent;
- Male or female, age≥18 years;
A female subject is eligible to enter the study if it is confirmed that she is:
- Of non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries removed or medically documented ovarian failure, or are postmenopausal-women > 50 years of age with cessation (for≥12 months) of previously occurring menses), or
- Of childbearing potential (Women≤50 years of age with amenorrhea will be considered to be of childbearing potential). These women must have a negative serum pregnancy test at screening, and must use specific contraceptive methods from screening until 4 weeks after last dose of study drugs, such as complete abstinence from intercourse, vaginal ring, cervical cap or contraceptive diaphragm, IUD, etc.
- All male study subjects must agree to consistently and correctly use specific contraceptive methods with their female partner from screening until 4 weeks after last dose of study drugs(except of surgical sterilization), such as complete abstinence from intercourse, condom, and their female partner use contraceptives , vaginal ring , cervical cap or contraceptive diaphragm, IUD, etc.
- Male subjects must agree to refrain from sperm donation from the date of screening until 4 weeks after the last dose of study drugs;
- Body mass index (BMI)≥18.0 and≤32.0 kg/m2, and Weight≥40 kg;
Confirmation of chronic HCV infection documented by either:
- A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or
- A liver biopsy performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection.
- Serological detection of anti-HCV antibodies was positive at screening;
- HCV RNA≥1×104 IU/mL at Screening;
- HCV genotype 1a, 1b, or mixed 1a/1b at screening as determined by the Central Laboratory;
Classification as treatment naive or treatment experienced:
- Treatment naive is defined as having never been exposed to approved or experimental HCV-specific direct-acting antiviral agents or prior treatment of HCV with interferon (with or without ribavirin);
- Treatment experienced is defined as prior treatment failure to a regimen containing interferon (IFN-α,β or Peg-IFN±RBV) that was completed at least 2 months prior to screening. and the subject's medical records must include sufficient detail of prior virologic failure to allow for categorization of prior response, as either:
i) Non-Responder: Decrease of HCV RNA<2 log at week 12 compared to baseline; ii) Partially-Responder: Decrease of HCV RNA>2 log at week 12 compared to baseline, and detectable HCV RNA levels within week 12 and week 24; iii) Breakthrough/Relapse: Subject achieved undetectable HCV RNA levels (HCV RNA < LLOQ) during treatment, but did not achieve sustained virologic response (SVR); iv) Intolerance: Subjects have discontinued interferon-based treatment due to intolerance which proved by chief complaint or medical records.
Absence of cirrhosis is defined as any one of the following:
- Liver biopsy within 2 years of Screening or at Screening showing absence of cirrhosis (e.g. Metavir score=0-3 or Ishak score<5), or
- Fibroscan within 6 months of Screening or at Screening with a result of ≤12.5 kPa.
liver biopsy results will supersede fibroscan results and be considered definitive.
- Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:
Current or prior history of any of the following:
- Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage);
- Chronic liver disease of a non-HCV etiology (Including but not limited to hemochromatosis, Wilson's disease,alfa-1 antitrypsin deficiency);
- Significant cardiac disease(Including but not limited to myocardial infarction, bradycardia) ;
- Significant pulmonary disease;
- Malabsorption syndrome or gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug;
- Central nervous system trauma, epilepsy, stroke or transient ischemic attack;
- Psychiatric illness or psychological disease or relevant medical history;
- Malignancy diagnosed before signing the informed consent form ( except for specific cancers that have been cured by surgical resection (basal cell skin cancer, etc) or cervical carcinoma in situ are allowed). subjects under evaluation for malignancy are not eligible;
- Solid organ transplantation;
- Subjects have any other medical disorder that may interfere with subjects treatment, assessment or compliance with the protocol.
Subjects has the following laboratory parameters at screening:
- ALT > 10×the upper limit of normal (ULN);
- AST > 10×ULN;
- Total bilirubin> 1.5 × ULN;
- Albumin< 3.5 g/dL;
- AFP>100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, a liver ultrasound examination is required to exclude subjects suspected of hepatocellular carcinoma;
- INR > 1.5 x ULN;
- Hemoglobin<11 g/dL for female subjects; <12 g/dL for male subjects;
- Platelets<90 x109/L;
- Neutrophil absolute count< 1.5 ×109/L;
- HbA1c > 8.5%;
- Creatinine clearance (CLcr) <50 mL /min as calculated by the Cockcroft-Gault equation;
- HBsAg serology test results were positive;
- HIV antibody test results were positive.
- Screening ECG with clinically significant abnormalities;
- Prior exposure to approved or experimental HCV-specific direct-acting antiviral agent;
- Use of any prohibited concomitant medications;
- Significant drug allergy, or known hypersensitivity to DAG181, SOF and its metabolites, or formulation recipients;
- A positive drug screen at screening will exclude subjects unless it can be explained by non-prescription drug or prescribed medication; the diagnosis and prescription must be approved by the investigator;
- Pregnant or nursing female or male with pregnant female partner.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: SOF+DAG181 100 mg
Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
|
Compressa da 400 mg somministrata per via orale una volta al giorno
Altri nomi:
Capsule administered orally once daily
Altri nomi:
|
Sperimentale: SOF+DAG181 200 mg
Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
|
Compressa da 400 mg somministrata per via orale una volta al giorno
Altri nomi:
Capsule administered orally once daily
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of subjects with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)
Lasso di tempo: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment
|
Posttreatment Week 12
|
Safety and tolerability were evaluated based on adverse event monitoring, laboratory tests, 12-lead ECG assessments, vital signs measurements and physical examinations.
Lasso di tempo: Up to posttreatment week 24
|
Up to posttreatment week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of subjects with sustained virologic response 4, 8 and 24 weeks after discontinuation of therapy (SVR4,SVR8 and SVR24)
Lasso di tempo: Posttreatment Weeks 4,8 and 24
|
SVR4,SVR8 and SVR24 were defined as HCV RNA < the lower limit of quantitation (LLOQ) at 4, 8 and 24 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4,8 and 24
|
Percentage of subjects with HCV RNA < the lower limit of quantitation (LLOQ) while on treatment
Lasso di tempo: Baseline to week 12
|
Baseline to week 12
|
|
The time to first achieve "HCV RNA < the lower limit of quantitation (LLOQ)" while on treatment
Lasso di tempo: Baseline to week 12
|
Baseline to week 12
|
|
HCV RNA change from baseline
Lasso di tempo: Up to posttreatment week 24
|
Up to posttreatment week 24
|
|
Percentage of subjects with virologic failure
Lasso di tempo: Up to posttreatment week 24
|
Virologic failure was defined as:
|
Up to posttreatment week 24
|
Viral resistance
Lasso di tempo: Up to posttreatment week 24
|
Viral resistance to DAG181 and/or SOF during treatment and after cessation of treatment
|
Up to posttreatment week 24
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PCD-DDAG181PA-16-005
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezione cronica da HCV
-
Ascletis Pharmaceuticals Co., Ltd.Completato
-
Ain Shams UniversityCompletato
-
PfizerCompletato
-
Bristol-Myers SquibbCompletatoHCV (genotipo 1)Stati Uniti, Porto Rico
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Reclutamento
-
Tibotec Pharmaceuticals, IrelandCompletato
-
Assiut UniversitySconosciuto
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases (NIAID)Completato
-
Kirby InstituteAustralasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM) e altri collaboratoriReclutamento
-
Beckman Coulter, Inc.Completato
Prove cliniche su SOF
-
McMaster UniversityAgency for Healthcare Research and Quality (AHRQ); Grading of Recommendations...Completato
-
Sanjay Gandhi Postgraduate Institute of Medical...Ram Manohar Lohia Institute of Medical Sciences, LucknowTerminato
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityReclutamentoInfezione cronica da epatite CCina
-
Humanity & Health Medical Group LimitedRitiratoInfezione da HCVHong Kong
-
Gilead SciencesTerminatoInfezione da virus dell'epatite CFrancia, Spagna, Stati Uniti, Australia, Canada, Germania, Regno Unito, Italia, Nuova Zelanda, Porto Rico
-
Humanity and Health Research CentreBeijing 302 HospitalCompletatoInfezione cronica da epatite CCina
-
Gilead SciencesCompletatoInfezione da virus dell'epatite CStati Uniti, Porto Rico
-
Stanford UniversityGilead SciencesCompletato
-
Humanity and Health Research CentreUniversity of Maryland; Emory University; Beijing 302 HospitalRitiratoInfezione cronica da epatite CHong Kong
-
Gilead SciencesCompletatoInfezione da virus dell'epatite CStati Uniti, Francia, Nuova Zelanda, Canada, Germania, Porto Rico, Regno Unito, Australia, Italia